Embrace Systems Corp. EMBC 深 滬
已收盤 09-19 16:00:00 美东时间
15.71
+0.200
+1.29%
華盛通- 最 高15.96
- 今 開15.93
- 成交量 45.59万股
- 最 低 15.48
- 昨 收 15.51
- 總市值 9.05亿
- 52周最高 19.34
- 市盈率 靜 12.89
- 換手率 0.79%
- 52周最低 9.625
- 委 比 65.99%
- 總股本 5757.89万
- 歷史最高 35.44
- 量 比 1.40
- 振 幅 3.09%
- 歷史最低 9.625
- 每 手 1
- 風險率 2.16%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多BTIG Reaffirms Their Hold Rating on Embecta Corporation (EMBC)
In a report released yesterday, Marie Thibault from BTIG reiterated a Hold rati...
09-04 20:19
Embecta gets FDA clearance for type 2 diabetes patch pump
Embecta (NASDAQ:EMBC) has received FDA clearance for its disposable insulin delivery system for the treatment of both type 1 and type 2 diabetes. The system includes a tubeless patch pump with a 300-u...
09-03 22:24
Embecta Corporation Announces Chief Accounting Officer Resignation
Embecta Corporation (EMBC) has provided an update. Embecta Corp. has announced ...
08-13 05:30
Embecta Corp.'s (NASDAQ:EMBC) Intrinsic Value Is Potentially 61% Above Its Share Price
Key Insights Embecta's estimated fair value is US$24.76 based on 2 Stage Free...
08-12 21:08
Genpact Supports embecta's Spin-Off into an Independent Diabetes Care Company
Genpact's deep domain knowledge and data expertise enables embecta's vision to make a meaningful impact in the healthcare sector NEW YORK, July 29, 2024 /PRNewswire/ -- Genpact (NYSE: G), a ...
07-29 20:05
Insulin Device Maker Embecta Weighs Sale After 70% Share Decline Following Becton Dickinson Spin-Off
Embecta is exploring a potential sale after a nearly 70% drop in share price since its spin-off from Becton Dickinson. The company's U.S. business has struggled with the rise of GLP-1 drugs and declining margins.
07-24 03:05
美股牛股 | Tellurian涨超68%，获澳洲油气巨头9亿美元溢价收购；Cassava涨超27%
Tellurian涨超68%，获澳洲油气巨头9亿美元溢价收购；Cassava涨超27%，公司透露药物研究情况反应积极>>
07-23 19:36
IQVIA Posts Upbeat Earnings, Joins Terex, Reddit And Other Big Stocks Moving Higher On Monday
U.S. stocks were higher, with the Nasdaq Composite gaining over 100 points on M...
07-22 23:28
Diabetes device maker Embecta exploring sale - FT
Diabetes device maker Embecta (NASDAQ:EMBC) has hired advisers to evaluate a potential sale as its shares have languished over the past two years after the company was spun off from Beckton Dickinson ...
07-22 19:10
Zimmer Biomet Announces Appointment of Devdatt Kurdikar to Board of Directors
WARSAW, Ind., June 20, 2024 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that Devdatt "Dev" Kurdikar, President, Chie...
06-20 19:30
